2026 Global: Alzheimer'S Disease Treatments Market -Competitive Review (2032) report
Description
The 2026 Global: Alzheimer'S Disease Treatments Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for alzheimer's disease treatments market by geography and historical trend. The scope of the report extends to sizing of the alzheimer's disease treatments market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
F. Hoffmann‑La Roche (Roche), Biogen, Eisai, Eli Lilly, AbbVie, Johnson & Johnson, Sanofi, AstraZeneca, TauRx (including parent/partners), and Anavex (representing emerging specialty players) are among the ten major companies shaping the global Alzheimer’s disease treatments market through complementary portfolios of anti‑amyloid and anti‑tau biologics, small molecules, platform technologies for CNS delivery, and strategic acquisitions that expand R&D pipelines. Roche remains prominent for its long history and broad neuroscience programs and antibody candidates, while Biogen — in partnership with Eisai — achieved a landmark with the anti‑amyloid antibody lecanemab (LEQEMBI), validating disease‑modifying potential and reinvigorating investment in anti‑Aβ approaches. Eli Lilly’s donanemab (Kisunla) added to regulatory momentum for amyloid‑targeting monoclonals and prompted renewed focus on biomarker‑driven trials and real‑world access planning, intensifying competition among large pharmas to deliver scalable disease‑modifying therapies. AbbVie has expanded its CNS capabilities through acquisitions such as Aliada Therapeutics to gain BBB‑crossing delivery technologies and novel anti‑amyloid candidates, signaling a strategic pivot by big biopharma toward enabling platforms as well as proprietary therapeutics.
Beyond amyloid, major players are diversifying into tau, innate immunity and synaptic/neuroprotective mechanisms to address late‑stage disease and heterogeneous patient populations. Johnson & Johnson’s increased neurology M&A and pipeline investments, along with Sanofi’s purchases (for example, Vigil Neuroscience) and collaborations, illustrate industrywide moves to acquire differentiated modalities such as TREM2 agonists and small‑molecule neuroinflammation agents that target microglial pathways and disease biology beyond plaques. AstraZeneca and other large multinationals are leveraging internal discovery and external partnerships to advance both oral small molecules and biologics aimed at tau aggregation, synaptic resilience, or neuroinflammation, recognizing that combination or sequential therapeutic strategies will likely be needed to achieve meaningful, durable clinical benefits. Specialty companies such as TauRx and Anavex, plus a vibrant cohort of biotech startups, continue to drive innovation in oral tau inhibitors, sigma‑1 receptor modulators, and novel screening platforms; conference and pipeline reports in 2025 highlighted late‑stage data from several of these smaller innovators, underscoring their role as sources of next‑generation assets that larger companies often acquire or in‑license.
Market dynamics now combine regulatory precedents, payer negotiations, and accelerated M&A to scale promising candidates from trials to clinical use while addressing access, safety monitoring, and biomarker infrastructure. Regulatory approvals for amyloid‑targeting antibodies have catalyzed dealmaking and funding — transfers of talent and assets into big pharma pipelines (for example, Johnson & Johnson’s and AbbVie’s transactions) have driven deal values sharply upward and fueled venture and nonprofit investment into early‑stage dementia funds. Commercial forecasts and conference projections project multibillion‑dollar revenues for successful disease‑modifying agents, incentivizing continued investment in diagnostic capacity (amyloid/tau PET, plasma biomarkers), risk mitigation programs, and combination trials; these ecosystem investments further entrench the listed major companies as central actors in translating scientific advances into broadly accessible Alzheimer’s treatments.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for alzheimer's disease treatments market by geography and historical trend. The scope of the report extends to sizing of the alzheimer's disease treatments market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
F. Hoffmann‑La Roche (Roche), Biogen, Eisai, Eli Lilly, AbbVie, Johnson & Johnson, Sanofi, AstraZeneca, TauRx (including parent/partners), and Anavex (representing emerging specialty players) are among the ten major companies shaping the global Alzheimer’s disease treatments market through complementary portfolios of anti‑amyloid and anti‑tau biologics, small molecules, platform technologies for CNS delivery, and strategic acquisitions that expand R&D pipelines. Roche remains prominent for its long history and broad neuroscience programs and antibody candidates, while Biogen — in partnership with Eisai — achieved a landmark with the anti‑amyloid antibody lecanemab (LEQEMBI), validating disease‑modifying potential and reinvigorating investment in anti‑Aβ approaches. Eli Lilly’s donanemab (Kisunla) added to regulatory momentum for amyloid‑targeting monoclonals and prompted renewed focus on biomarker‑driven trials and real‑world access planning, intensifying competition among large pharmas to deliver scalable disease‑modifying therapies. AbbVie has expanded its CNS capabilities through acquisitions such as Aliada Therapeutics to gain BBB‑crossing delivery technologies and novel anti‑amyloid candidates, signaling a strategic pivot by big biopharma toward enabling platforms as well as proprietary therapeutics.
Beyond amyloid, major players are diversifying into tau, innate immunity and synaptic/neuroprotective mechanisms to address late‑stage disease and heterogeneous patient populations. Johnson & Johnson’s increased neurology M&A and pipeline investments, along with Sanofi’s purchases (for example, Vigil Neuroscience) and collaborations, illustrate industrywide moves to acquire differentiated modalities such as TREM2 agonists and small‑molecule neuroinflammation agents that target microglial pathways and disease biology beyond plaques. AstraZeneca and other large multinationals are leveraging internal discovery and external partnerships to advance both oral small molecules and biologics aimed at tau aggregation, synaptic resilience, or neuroinflammation, recognizing that combination or sequential therapeutic strategies will likely be needed to achieve meaningful, durable clinical benefits. Specialty companies such as TauRx and Anavex, plus a vibrant cohort of biotech startups, continue to drive innovation in oral tau inhibitors, sigma‑1 receptor modulators, and novel screening platforms; conference and pipeline reports in 2025 highlighted late‑stage data from several of these smaller innovators, underscoring their role as sources of next‑generation assets that larger companies often acquire or in‑license.
Market dynamics now combine regulatory precedents, payer negotiations, and accelerated M&A to scale promising candidates from trials to clinical use while addressing access, safety monitoring, and biomarker infrastructure. Regulatory approvals for amyloid‑targeting antibodies have catalyzed dealmaking and funding — transfers of talent and assets into big pharma pipelines (for example, Johnson & Johnson’s and AbbVie’s transactions) have driven deal values sharply upward and fueled venture and nonprofit investment into early‑stage dementia funds. Commercial forecasts and conference projections project multibillion‑dollar revenues for successful disease‑modifying agents, incentivizing continued investment in diagnostic capacity (amyloid/tau PET, plasma biomarkers), risk mitigation programs, and combination trials; these ecosystem investments further entrench the listed major companies as central actors in translating scientific advances into broadly accessible Alzheimer’s treatments.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.